BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2004
 |  BioCentury  |  Emerging Company Profile

Evolva: Swiss Watchmaker

The chemistry bottleneck in drug discovery is defined by the time and cost required to identify and synthesize new compounds. Evolva Ltd. says its Watchmaker yeast-based technology helps it discover compounds faster than traditional high throughput screening and medicinal chemistry methods. The company adds that it also can create compounds that are hard to make using other techniques.

Watchmaker introduces hundreds of genes into yeast and uses the innate evolutionary power of these cells to perform high throughput drug discovery and lead optimization.

Watchmaker works in three steps. The first is to build a large combinatorial genetic library in yeast. Second is to manage growth of the yeast in a way that results in novel compounds. Third is to perform compound selection.

Evolva sources animal and plant material that express...

Read the full 641 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >